Q1 Earnings Forecast for TPST Issued By HC Wainwright

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Tempest Therapeutics in a research report issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.39) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $12.50.

Tempest Therapeutics Trading Down 1.2%

Tempest Therapeutics stock opened at $1.62 on Thursday. Tempest Therapeutics has a 12-month low of $1.50 and a 12-month high of $12.23. The firm has a 50-day moving average price of $2.31 and a 200-day moving average price of $5.12. The firm has a market capitalization of $7.98 million, a PE ratio of -0.24 and a beta of -2.42.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.62) earnings per share for the quarter, meeting the consensus estimate of ($0.62).

Insider Buying and Selling

In other Tempest Therapeutics news, CEO Matthew Angel purchased 231,482 shares of the stock in a transaction on Tuesday, March 24th. The shares were bought at an average cost of $2.16 per share, with a total value of $500,001.12. Following the completion of the acquisition, the chief executive officer owned 231,482 shares in the company, valued at $500,001.12. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.28% of the company’s stock.

Institutional Trading of Tempest Therapeutics

Hedge funds have recently modified their holdings of the stock. Sabby Management LLC purchased a new stake in shares of Tempest Therapeutics in the fourth quarter valued at approximately $513,000. Dimensional Fund Advisors LP purchased a new position in shares of Tempest Therapeutics during the fourth quarter worth about $33,000. Finally, Vanguard Group Inc. grew its stake in Tempest Therapeutics by 20.8% during the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after buying an additional 27,952 shares during the last quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.